Differential enzymatic reductions governing the differential hypoxia-selective cytotoxicities of phenazine 5,10-dioxides

Chemical Research in Toxicology

Volumn 21, Issue 9, 2008, Pages 1900-1906

  Lavaggi, María Laura ^a   Cabrera, Mauricio ^a   González, Mercedes ^a   Cerecetto, Hugo ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DICOUMAROL; DIHYDROLIPOAMIDE DEHYDROGENASE; KETOCONAZOLE; OXIDOREDUCTASE; PHENAZINE 5,10 DIOXIDE; PHENAZINE DERIVATIVE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CYTOSOL; CYTOTOXICITY; DRUG METABOLISM; HYPOXIA; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; RAT;

ALDEHYDE OXIDASE; ANIMALS; ANOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; DICUMAROL; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; PHENAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 53549100988     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800199v     Document Type: Article

References (51)

1. 2 histography. In Tumor Oxygenation (Vaupel, P. W., Kelleher, D. K., and Gunderoth, M., Eds.) pp 219-232, Gustav Fischer, Germany.
2. Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., and Scott, O. C. (1953) Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26, .638-648.
3. Cerecetto, H., González, M., and Lavaggi, M. L. (2006) Development of selective hypoxic cytotoxins for cancer treatment: an update. Med. Chem. 2, 315-327.
4. Patterson, L. H. (2002) Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug. Metab. Rev. 34, 581-592.
5. Lee, D. J., Trotti, A., Spencer, S., Rostock, R., Fisher, C., von Roemeling, R., Harvey, E., and Groves, E. (1998) Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study. Int. J. Radiat. Oncol. Biol. Phys. 42, 811-815.
6. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., and Treat, J. (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the International CATAPULT I study group. J. Clin. Oncol. 18, 1351-1359.
7. Wang, J., Biedermann, K. A., and Brown, J. M. (1992) Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52, 4473-4477.
8. 2. J. Am. Chem. Soc. 129, 12870-12877.
9. Baker, M. A., Zeman, E. M., Hirst, V. K., and Brown, J. M. (1988) Metabolism of SR4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res. 48, 5947-5952.
10. Laderoute, K., Wardman, P., and Rauth, A. M. (1988) Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-l,4-dioxide (SR 4233). Biochem. Pharmacol. 37, 1487-1495.
11. Wang, J., Biedermann, K. A., Wolf, C. R., and Brown, J. M. (1993) Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br. J. Cancer 67, 321-325.
12. Patterson, A. V., Robertson, N., Houlbrook, S., Stephens, M. A., Adams, G. E., Harris, A. L., Stratford, I. J., and Carmichael, J. (1994) The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233). Int. J. Radiat. Oncol. Biol. Phys. 29, 369-372.
13. Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., and Stratford, I. J. (1995) Importance of P450 reductase activity in determining sensitivity of breast tumor cells to the bioreductive drug tirapazamine (SR 4233). Br. J. Cancer 72, 1144-1150.
14. Patterson, A. V., Saunders, M. P., Chinje, E. C., Patterson, L. H., and Stratford, I. J. (1998) Enzymology of tirapazamine metabolism: A review. Anti-Cancer Drug Des. 13, 541-573.
15. Delahoussaye, Y. M., Evans, J. W., and Brown, J. M. (2001) Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol. 62, 1201-1209.
16. Solano, B., Junnotula, V., Marín, A., Villar, R., Burguete, A., Vicente, E., Pérez-Silanes, S., Aldana, I., Monge, A., Dutta, S., Sarkar, U., and Gates, K. S. (2007) Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluorornethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J. Med. Chem. 50, 5485-5492.
17. Patterson, L. H., Craven, M. R., Fisher, G. R., and Teesdale-Spittle, P. (1994) Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol. Res. 6, 533-538.
18. Wilson, W. R., Denny, W. A., Pullen, S. M., Thompson, K. M., Patterson, L. H., and Li, A. E. (1996) Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, NitracrineN-oxide and AQ4N. Br. J. Cancer 74, S43-47.
19. Smith, P. J., Blunt, J. N., Desnoyers, R., Giles, Y., and Patterson, L. H. (1997) DNA topoisomerase II-dependent cytotoxicity of alky- laminoanthraquinones and their N-oxides. Cancer Chemother. Pharmacol. 39, 455-461.
20. Raleigh, S. M., Wanogho, E, Buike, M. D., and Patterson, L. H. (1999) Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug. Xenobiotica 29, 1115-1122.
21. Raleigh, S. M., Wanogho, E., Burke, M. D., McKeown, S. R., and Patterson, L. H. (1998) Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int. J. Radial. Oncol. Biol. Phys. 42, 763-767.
22. Cerecetto, H., González, M., Onetto, S., Risso, M., Saenz, P., Seoane, G., Monge, A., López de Ceráin, A., Ezpeleta, O., Olea-Azar, C., and Bruno, A. M. (2001) 1,2,4-Triazine N-oxide and di-N-oxide derivatives. Synthesis and evaluation as hypoxia selective cytotoxins. Med Chem. Res. 10, 328-337.
23. Cerecetto, H., González, M., Onetto, S., Saenz, P., Ezpeleta, O., López de Ceráin, A., and Monge-Vega, A. (2004) 1,2,4-Triazine N-oxide derivatives: Studies as potential hypoxic cytotoxins. Part n. Arch. Pharm. 337, 247-258.
24. Cerecetto, H., González, M., Risso, M., Saenz, P., Olea-Azar, C., Bruno, A. M., Azqueta, A., López de Ceráin, A., and Monge, A. (2004) 1,2,4-Triazine N-oxide derivatives: Studies as potential hypoxic cytotoxins Part HI. Arch. Pharm. 337, 271-280.
25. Boiani, M., Cerecetto, H., González, M., Risso, M., Olea-Azar, C., Ezpeleta, O., López de Ceráin, A., and Monge, A. (2001) 1,2,5-Oxadiazole N-oxide derivatives as potential anti-cancer agents: Synthesis and biological evaluation. Part IV. Eur. J. Med. Chem. 36, 771-782.
26. Boiani, M., Cerecetto, H., and González, M. (2004) Cytotoxicity of furoxans: Quantitative structure-activity relationships study. Farmaco 59, 405-412.
27. Aguirre, G., Boiani, M., Cerecetto, H., Fernández, M., González, M., León, E., Pintos, C., Raymondo, S., Arredondo, C., Pacheco, J. P., and Basombrío, M. A. (2006) Furoxan derivatives as cytotoxic agents: Preliminary in vivo antitumoral activity studies. Pharmazie 61, 54-59.
28. Cerecetto, H., González, M., Onetto, S., Risso, M., Rey, A., Giglio, J., León, E., León, A., Pilatti, P., and Fernández, M. (2006) Synthesis and characterization of thiol containing furoxan derivatives as coligands for the preparation of potential bioreductive. Arch. Pharm. 339, 59-66.
29. Giglio, J., Rey, A., Cerecetto, H., Pirmettis, I., Papadopoulos, M., León, E., Monge, A., López de Ceráin, A., Azqueta, A., González, M., Fernández, M., Paolino, A., and León, A. (2006) Design and evaluation of "3 + 1" mixed ligand oxorhenium and oxotechnetium complexes bearing a nitroaromatic group with potential application in nuclear medicine oncology. Eur. J. Med. Chem. 41, 1144-1152.
30. 10-dioxides. Effects of benzofuroxan substituents in the outcome of their expansion reaction with phenolates. J. Braz. Chem. Soc. 6, 1290-1296.
31. Cerecetto, H., González, M., Lavaggi, M. L., Azqueta, A., López de Ceráin, A., and Monge, A. (2005) Phenazine 5,10-iioxide derivatives as hypoxic selective cytotoxins. J. Med Chem. 48, 21-23.
32. Cerecetto, H., González, M., Lavaggi, M. L., Aravena, M. A., Rigol, C., Olea-Azar, C., Azqueta, A., López de Ceráin, A., Monge, A., and Bruno, A. M. (2006) Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins. Part II. Structure - activity relationship studies. Med. Chem. 2, 511-521.
33. 10-dioxide derivatives on Caco-2 cells. Chem. Res. Toxicol., DOI: 10.1021/ tx800032k.
34. Issidorides, C. H., and Haddadin, M. J. (1966) Benzofurazan oxide, II. Reactions with enolate anions. J. Org. Cham. 31, 4067-4068.
35. Naylor, M. A., and Thomson, P. (2001) Recent advances in bioreductive drug targeting. Mini Rev. Med Chem. 1, 17-29.
36. Mangnino, M. E., and Brunner, J. R. (1976) Isolation and partial characterization of xanthine oxidase associated with the milk fat globule membrane of cows milk. J. Dairy Sci. 60, 841-850.
37. Morton, D. B., and Griffiths, P. H. M. (1985) Guidelines on the recognition of pain, distress and discomfort in experimental animal and a hypothesis for assessment. Vet. Rec. 116, 431-436.
38. Jiang, Z., Chen, C., Yang, B., Hebbar, V., and Kong, A. (2003) Differential responses from seven mammaliam cell Unes to the treatments of detoxifying enzyme inducers. Life Sci. 72, 2243-2253.
39. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., and Mayer, R. T. (1985) Ethoxy-pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34,3337-3345.
40. Koshiba, T., Saito, E., Ono, N., Yamamoto, N., and Sato, M. (1996) Purification and properties of flavin- and molybdenum-containing aldehyde oxidase from coleoptiles of maize. Plant Physiol. 110, 781-789.
41. Grosa, G., Galli, U., Rolando, B., Fruttero, R., Gervasio, G., and Gasco, A. (2004) Identification of 2,3-diaminophenazine and of o-benzo-quinone dioxime as the major in vitro metabolites of benzofuroxan. Xenobiotica 34, 345-352.
42. Daniels, J. S., and Gates, K. S. (1996) DNA cleavage by the antitumor agent 3-amino-1 ,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc. 118, 3380-3385.
43. Sun, Z.-Y., Botros, E., Su, A.-D., Kim, Y., Wang, E., Baturay, N. Z., and Kwon, C.-H. (2000) Sulfoxide-containing aromatic nitrogen mustards as hypoxia-directed bioreductive cytotoxins. J. Med Chem. 43, 4160-4168.
44. Hargreaves, R. H. J., O'Hare, C. C., Hartley, J. A., Ross, D., and Butler, J. (1999) Cross-linking and sequence-specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents. J. Med Chem. 42, 2245-2250.
45. Danson, S., Ward, T. H., Butler, J., and Ranson, M. (2004) DT-Diaphorase: A target for new anticancer drugs. Cancer Treat. Rev. 30, 437-449.
46. Siegel, D., Gibson, N. W., Preusch, P. C., and Ross, D. (1990) Metabolism of Mitomycin C by DT-diaphorase: Role in Mitomycin C induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 50, 7483-7489.
47. Walton, M. I., Smith, P. I., and Workman, P. (1991) The role of NAD(P)H:quinone oxidoreductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent E09. Cancer Commun. 3, 199-206.
48. Pardee, A. B., Li, Y. Z., and Li, C. J. (2002) Cancer therapy with β-lapachone. Curr. Cancer Drug Targets 2, 227-242.
49. Nagai, K., Carter, B. J., Xu, J., and Hecht, S. M. (1991) DNA cleavage by oxygen radicals produced in die absence of metal ions or light J Am. Chem. Soc. 113, 5099-5100.
50. Nagai, K., and Hecht, S. M. (1991) Site-specific DNA cleavage by antisense oligonucleotides covalently linked to phenazine di-N-oxide. J. Biol. Chem. 266, 23994-24002.
51. Chowdhury, G., Kotandeniya, D., Daniels, J. S., Barnes, C. L., and Gates, K. S. (2004) Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide. Chem. Res. Toxicol. 17, 1399-1405.